Plain-English peptide research. Affiliate links are disclosed.

VeritideVeritide

CJC-1295

Also cited in the literature as CJC-1295 with DAC / modified GRF

A modified growth-hormone-releasing peptide designed to last longer in the blood. Only early-phase human data was published before development stopped.

Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.

Illustration of peptide chains and cell-surface receptors

Hormone & signalling research

Research stage: Phase 1 results published; development discontinued

Cells
Animal studies
Human trials

The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.

What it is

CJC-1295 is a modified version of growth-hormone-releasing hormone. In the version described as "with DAC", a chemical group lets it attach to a blood protein so it stays in circulation far longer.

How researchers think it works

Papers described the same pituitary receptor target as sermorelin, with the added attachment intended to extend how long the signal lasted.

What has research seen in people?

One published early-phase study in healthy adults reported growth hormone and IGF-1 readings staying raised for several days after it was given.

That is the extent of the human evidence — no later trials were published and development stopped.

Nothing about repeated or longer-term use in people is established.

Where this material is listed

For laboratory research use only. Not a medicine and not for human or animal use.

CJC-1295 with DACResearch materialCJC-1295 with DAC£49.99View listing ›CJC-1295 (No DAC) x Ipamorelin (Blend)Research materialCJC-1295 (No DAC) x Ipamorelin (Blend)£49.99View listing ›

Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.

What studies have found

  • A phase 1 study published in the Journal of Clinical Endocrinology & Metabolism in healthy adults reported sustained rises in growth hormone and IGF-1 measurements over several days.
  • No later-phase trials were published, and the development programme did not continue to approval.

What we still do not know

  • The published human evidence is a single small early-phase study measuring hormone levels, not health outcomes.
  • Nothing about long-term safety in people is established.

Sources

Related profiles

Retatrutide

Triple incretin receptor agonist

An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.

Mazdutide

Dual GLP-1 / glucagon receptor agonist

An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.

BPC-157

Synthetic pentadecapeptide

A laboratory-made peptide made of 15 amino acids. Almost all published research involved cells or rodents rather than people.